1
|
Zhao X, Qu Q, Zhang Y, Zhao P, Zhang X, Tang Y, Lei X, Wei X, Song X. Mechanism of Xing 9 ling tablet candy for alcoholic liver disease based on network pharmacology. Anal Biochem 2024; 691:115534. [PMID: 38621605 DOI: 10.1016/j.ab.2024.115534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2023] [Revised: 04/04/2024] [Accepted: 04/08/2024] [Indexed: 04/17/2024]
Abstract
Xing 9 Ling tablet candy (X9LTC) effectively treats alcoholic liver disease (ALD), but its potential mechanism and molecular targets remain unstudied. We aimed to address this gap using network pharmacology. Furthermore, high-performance liquid chromatography (HPLC) and database analysis revealed a total of 35 active ingredients and 311 corresponding potential targets of X9LTC. Protein interaction analysis revealed PTGS2, JUN, and FOS as its core targets. Enrichment analysis indicated that chemical carcinogenesis-receptor activation, IL-17 and TNF signaling pathway were enriched by multiple core targets, which might be the main pathway of action. Further molecular docking validation showed that the core targets had good binding activities with the identified compounds. Animal experiments showed that X9LTC could reduce the high expression of ALT, AST and TG in the serum of ALD mice, alleviate the lesions in liver tissues, and reverse the high expression of PTGS2, JUN, and FOS proteins in the liver tissues. In this study, we established a method for the determination of X9LTC content for the first time, and predicted its active ingredient and mechanism of action in treating ALD, providing theoretical basis for further research.
Collapse
Affiliation(s)
- Xiaomei Zhao
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
| | - Qiong Qu
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
| | - Ying Zhang
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
| | - Peiyuan Zhao
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
| | - Xinbo Zhang
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
| | - Yingying Tang
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
| | - Xuan Lei
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
| | - Xuan Wei
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
| | - Xiao Song
- Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China; Engineering Research Center for Pharmaceutics of Chinese Materia Medica and New Drug Development, Ministry of Education, Beijing, 100029, China.
| |
Collapse
|